Class of depressant drugs derived from barbituric acid
Class of depressant drugs derived from barbituric acid
Barbiturates are a class of depressant drugs that are chemically derived from barbituric acid. They are effective when used medically as anxiolytics, hypnotics, and anticonvulsants, but have physical and psychological addiction potential as well as overdose potential among other possible adverse effects. They have been used recreationally for their anti-anxiety and sedative effects, and are thus controlled in most countries due to the risks associated with such use.
Barbiturates have largely been replaced by benzodiazepines and nonbenzodiazepines ("Z-drugs") in routine medical practice, particularly in the treatment of anxiety disorders and insomnia, because of the significantly lower risk of overdose, and the lack of an antidote for barbiturate overdose. Despite this, barbiturates are still in use for various purposes: in general anesthesia, epilepsy, treatment of acute migraines or cluster headaches, acute tension headaches, euthanasia, capital punishment, and assisted suicide.
Harm Reduction
General Principles Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual sensitivity varies enormously. Test your substances: Use reagent t...
The barbiturate class comprises GABA-A receptor modulators that produce a characteristic spectrum of effects ranging from mild sedation to surgical anesthesia and, at sufficient doses, death. As a class, they share a signature that is recognizably distinct from benzodiazepines.
The general barbiturate experience involves a heavy, warm sedation accompanied by euphoria, muscle relaxation, and dissolution of anxiety. The quality of the sedation is often described as warmer, deeper, and more narcotic than that of benzodiazepines, with a blissful, heavy contentment that is powerfully reinforcing. Cognitive impairment is pronounced, with slowed thinking, impaired judgment, and significant memory disruption.
The class is defined by its narrow therapeutic index: the distance between an effective dose and a lethal dose is small and variable. This lack of a ceiling effect, combined with the euphoria that encourages escalating use, made barbiturates one of the most dangerous classes of prescription drugs before their replacement by benzodiazepines. Duration varies widely across the class, from the ultra-short pentobarbital to the very long-acting phenobarbital. Physical dependence develops rapidly, and withdrawal can be fatal.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(9)
Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Tremors— Involuntary rhythmic shaking of the hands, limbs, or body, ranging from fine tremor to gross shaking...
Cognitive & Perceptual Effects
Cognitive(12)
Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
Pharmacology
Barbiturates act as positive allosteric modulators, and at higher doses, as agonists of GABAA receptors. GABA is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS). Barbiturates bind to the GABAA receptor at multiple homologous transmembrane pockets located at subunit interfaces, which are binding sites distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. In addition to this GABAergic effect, barbiturates also block AMPA and kainate receptors, subtypes of ionotropic glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Taken together, the findings that barbiturates potentiate inhibitory GABAA receptors and inhibit excitatory AMPA receptors can explain the superior CNS-depressant effects of these agents to alternative GABA potentiating agents such as benzodiazepines and quinazolinones. At higher concentration, they inhibit the Ca2+-dependent release of neurotransmitters such as glutamate via an effect on P/Q-type voltage-dependent calcium channels. Barbiturates produce their pharmacological effects by increasing the duration of chloride ion channel opening at the GABAA receptor (pharmacodynamics: This increases the efficacy of GABA), whereas benzodiazepines increase the frequency of the chloride ion channel opening at the GABAA receptor (pharmacodynamics: This increases the potency of GABA). The direct gating or opening of the chloride ion channel is the reason for the increased toxicity of barbiturates compared to benzodiazepines in overdose. Barbiturates, also facilitate accumulation of endogenous adenosine in the extracellular space by inhibiting adenosine uptake via adenosine transporters. The adenosine-induced depressions of excitatory synaptic transmissions probably contribute to the mechanisms of the anesthetic, sedative and anticonvulsant effects.
Further, barbiturates are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABAA receptor channel is only one of several representatives. This superfamily of ion channels includes the neuronal nACh receptor channel, the 5-HT3 receptor channel, and the glycine receptor channel. However, while GABAA receptor currents are increased by barbiturates (and other general anaesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR channels are blocked by clinically relevant anaesthetic concentrations of both thiopental and pentobarbital. Such findings implicate (non-GABA-ergic) ligand-gated ion channels, e.g. the neuronal nAChR channel, in mediating some of the (side) effects of barbiturates.[7a] This is the mechanism responsible for the (mild to moderate) anesthetic effect of barbiturates in high doses when used in anesthetic concentration.
Barbituric acid was first synthesized 27 November 1864, by German chemist Adolf von Baeyer. This was done by condensing urea with diethyl malonate. There are several stories about how the substance got its name. The most likely story is that Baeyer and his colleagues went to celebrate their discovery in a tavern where the town's artillery garrison were also celebrating the feast of Saint Barbara– the patron saint of artillerymen. An artillery officer is said to have christened the new substance by amalgamating Barbara with urea. Another story holds that Baeyer synthesized the substance from the collected urine of a Munich waitress named Barbara. No substance of medical value was discovered, however, until 1902 when two German scientists working at Bayer, Emil Fischer and Joseph von Mering, discovered that barbital was very effective in putting dogs to sleep. Barbital was then marketed by Bayer under the trade name Veronal. It is said that Mering proposed this name because the most peaceful place he knew was the Italian city of Verona. In 1912, Bayer introduced another barbituric acid derivative, phenobarbital, under the trade name Luminal, as a sedative–hypnotic.
It was not until the 1950s that the behavioral disturbances and physical dependence potential of barbiturates became recognized.
Since the 1970s, most barbiturates were replaced by benzodiazepines.
Barbituric acid itself does not have any direct effect on the central nervous system and chemists have derived over 2,500 compounds from it that possess pharmacologically active qualities. The broad class of barbiturates is further broken down and classified according to speed of onset and duration of action. Ultrashort-acting barbiturates are commonly used for anesthesia because their extremely short duration of action allows for greater control. These properties allow doctors to rapidly put a patient "under" in emergency surgery situations. Doctors can also bring a patient out of anesthesia just as quickly, should complications arise during surgery. The middle two classes of barbiturates are often combined under the title "short/intermediate-acting." These barbiturates are also employed for anesthetic purposes, and are also sometimes prescribed for anxiety or insomnia. This is not a common practice anymore, however, owing to the dangers of long-term use of barbiturates; they have been replaced by the benzodiazepines and Z-drug such as zolpidem, zaleplon and eszopiclone for sleep. The final class of barbiturates are known as long-acting barbiturates (the most notable one being phenobarbital, which has a half-life of roughly 92 hours). This class of barbiturates is used almost exclusively as anticonvulsants, although on rare occasions they are prescribed for daytime sedation. Barbiturates in this class are not used for insomnia, because, owing to their extremely long half-life, patients would awake with a residual "hang-over" effect and feel groggy.
Barbiturates can in most cases be used either as the free acid or as salts of sodium, calcium, potassium, magnesium, lithium, etc. Codeine- and dionine-based salts of barbituric acid have been developed.
Harm Reduction
General Principles
Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual sensitivity varies enormously.
Test your substances: Use reagent test kits to verify identity and check for dangerous adulterants. Consider using drug checking services where available.
Research thoroughly: Understand expected dose ranges, duration, potential interactions, and contraindications before use.
Never use alone: Have a trusted, sober person present, especially with new substances or higher doses.
Set and setting: Your mindset and environment profoundly influence the experience. Choose a safe, comfortable environment and ensure you're in a stable psychological state.
Barbiturates-Specific Harm Reduction
Respiratory depression: The primary danger of depressants. Never combine with other depressants (alcohol, opioids, other sedatives) — this dramatically increases the risk of fatal respiratory failure.
Dependence: Physical dependence can develop rapidly with regular use. Some depressantwithdrawal syndromes (particularly benzodiazepines and alcohol) can be life-threatening and require medical supervision to manage safely.
Amnesia risk: Many depressants cause anterograde amnesia (inability to form new memories). This can lead to accidental redosing and overdose. Do not keep additional doses accessible during use.
Taper, don't stop: If physically dependent, never stop abruptly. Work with a medical professional on a gradual tapering schedule.
Tolerance is not safety: Tolerance to subjective effects develops faster than tolerance to respiratory depression. The dose that "feels right" can be dangerously close to a lethal dose.
Toxicity & Safety
Barbiturates are toxic at higher dosages. Barbiturates have a greater addiction potential than benzodiazepines. Overdose can be achieved much more easily with barbiturates than with benzodiazepines. Some barbiturates, such as phenobarbital, have been linked to the development of cancer. Using barbiturates concurrently with other depressants can be considered extremely dangerous even when taken in lower doses, and may lead to severe negative side effects such as respiratory depression, coma, and death.
Tolerance and addiction potential
Barbiturates can be considered extremely physically and psychologically addictive. Shorter-acting barbiturates are significantly more addictive than longer-acting barbiturates.
Tolerance will develop to the sedative-hypnotic, anxiolytic, and euphoric effects of barbiturates after prolonged use. It is unknown exactly how long it takes for tolerance to reach baseline after continued use. All barbiturates present cross tolerance with each other, meaning that tolerance to one barbiturate will lead to tolerance of all other barbiturates.
Discontinuation
Chronic barbiturate use can cause severe withdrawal symptoms such as restlessness, tremors, hyperthermia, sweating, insomnia, anxiety, seizures, circulatory failure, and potentially death. Drugs which lower the seizure threshold such as tramadol and amphetamine should be avoided during withdrawal. If an individual is addicted to a shorter-acting barbiturate such as pentobarbital, switching to a longer-acting barbiturate such as phenobarbital may prove beneficial.
Overdose
Barbiturate overdose may occur when a barbiturate is taken in extremely heavy quantities or concurrently with other depressants. Combining barbiturates with other GABAergic depressants such as benzodiazepines and alcohol is particularly dangerous because they all work in a similar fashion but bind to distinct allosteric sites on the GABAA receptor, thus potentiating one another. Benzodiazepines increase the frequency in which the chlorine ion pore opens on the GABAA receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer. Barbiturate overdose is a medical emergency that is commonly known to induce coma, permanent brain injury, and death if it is not treated promptly by medical professionals. Barbiturate overdose has an increased frequency of serious adverse effects when compared to other depressants.
Extremely addictive. Barbiturates produce strong physical and psychological dependence. Tolerance to mood-altering effects develops rapidly, requiring dose escalation and increasing overdose risk. Withdrawal is potentially fatal, featuring seizures, delirium, autonomic instability, and psychosis. Barbiturate withdrawal is considered even more severe than alcohol or benzodiazepine withdrawal due to barbiturates' more direct GABA agonism mechanism.
Overdose Information
Depressant overdose from Barbiturates is a life-threatening medical emergency. The primary mechanism of death is respiratory depression leading to respiratory arrest.
Signs of overdose: Extremely slow or stopped breathing, blue lips or fingertips (cyanosis), pinpoint pupils, unresponsiveness, cold/clammy skin, gurgling or snoring sounds (may indicate airway obstruction), very slow heart rate.
Emergency response:
Call emergency services immediately
If the person is not breathing, begin rescue breathing or CPR
Place unconscious but breathing person in the recovery position
Administer naloxone if opioid involvement is suspected
Stay with the person until help arrives
Be honest with emergency responders about all substances consumed
Critical combination risk: The combination of Barbiturates with other depressants (alcohol, benzodiazepines, opioids) is the most common scenario for fatal depressant overdose. The respiratory depression from multiple depressants is synergistic (greater than the sum of individual effects).
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
The legal status of Barbiturates varies by jurisdiction and is subject to change. This information is provided for educational purposes and may not reflect the most current legislation.
General patterns: Many psychoactive substances are controlled under national and international drug control frameworks, including the United Nations Single Convention on Narcotic Drugs (1961), the Convention on Psychotropic Substances (1971), and country-specific legislation such as the US Controlled Substances Act, UK Misuse of Drugs Act, and EU Framework Decisions.
Research chemicals and analogues: Novel psychoactive substances may be captured by analogue laws (e.g., the US Federal Analogue Act) or blanket bans on substance classes (e.g., the UK Psychoactive Substances Act 2016), even if the specific compound is not individually scheduled.
Important note: Possessing, distributing, or manufacturing controlled substances carries serious legal consequences in most jurisdictions. Legal status is not a reliable indicator of a substance's safety profile — some highly dangerous substances are legal, while some with favorable safety profiles are strictly controlled.
Users are strongly encouraged to research the specific legal status of Barbiturates in their jurisdiction before any involvement with this substance.
Combining barbiturates with alcohol, opioids, or benzodiazepines is one of the most lethal drug combinations possible. The respiratory depression stacks multiplicatively, not additively. Many deaths attributed to barbiturates involve combinations.
OldSchoolSedation · Mar 4
Barbiturates have an extremely narrow therapeutic window compared to benzodiazepines. The difference between a recreational dose and a dangerous one is very small. Never eyeball doses.
PharmacologyNerd42 · Mar 4
Barbiturates are rarely prescribed today and street versions are often counterfeit or mislabeled. If you obtain any, reagent test them. Many supposed barbiturates are actually benzodiazepines or worse.
SafeUseAdvocate · Mar 4
Barbiturates have largely been replaced by benzodiazepines in medical practice because benzos have a much wider safety margin. If you are using barbiturates recreationally, consider that the risk-to-reward ratio is significantly worse than alternatives.
HarmRedux_RN · Mar 4
Keep a usage log for Barbiturates including dose, time, effects, and side effects. This helps you identify patterns and prevent problematic escalation.
DoseItRight_ · Mar 4
Always start with a low dose of Barbiturates and work your way up. Individual sensitivity varies, and you cannot undo a dose once taken.
Class of depressant drugs derived from barbituric acid Barbiturates are a class of depressant drugs that are chemically derived from barbituric acid. They are effective when used medically as anxiolytics, hypnotics, and anticonvulsants, but have physical and psychological addiction potential as well
What are the effects of Barbiturates?
The barbiturate class comprises GABA-A receptor modulators that produce a characteristic spectrum of effects ranging from mild sedation to surgical anesthesia and, at sufficient doses, death. As a class, they share a signature that is recognizably distinct from benzodiazepines. The general barbitura
Is Barbiturates addictive?
Extremely addictive. Barbiturates produce strong physical and psychological dependence. Tolerance to mood-altering effects develops rapidly, requiring dose escalation and increasing overdose risk. Withdrawal is potentially fatal, featuring seizures, delirium, autonomic instability, and psychosis. Ba
What are the risks of Barbiturates?
Barbiturates are toxic at higher dosages. Barbiturates have a greater addiction potential than benzodiazepines. Overdose can be achieved much more easily with barbiturates than with benzodiazepines. Some barbiturates, such as phenobarbital, have been linked to the development of cancer. Using barbit
Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
Emotion suppression— A blunting or flattening of emotional experience in which feelings become muted, distant, or seeming...
Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
